Cathie Wood Is Loading Up on This GLP-1 Stock That Has Soared 1,600% Over the Past 10 Years

3 weeks ago 10

Prosper Junior Bakiny, The Motley Fool

Sun, July 19, 2026 astatine 5:20 PM CDT 4 min read

Cathie Wood, the CEO of Ark Investment Management, is simply a staunch believer successful innovation. The steadfast she leads is known for investing successful companies making breakthroughs crossed assorted fields, including healthcare. One person successful the assemblage that Cathie Wood is doubling down connected is Eli Lilly (NYSE: LLY), the apical subordinate successful the GLP-1 market. Eli Lilly has made important breakthroughs implicit the past decade, and the banal has outperformed broader equities, gaining implicit 1,600% during this period. But tin the banal inactive present coagulated returns?

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

It could beryllium conscionable the opening

Eli Lilly's tirzepatide, a GLP-1 medicine indicated to dainty diabetes, value loss, and obstructive slumber apnea, is breaking records. Tirzepatide exceeded $30 cardinal successful yearly income past twelvemonth crossed each its indications, a feat astir unheard of for a medicine archetypal approved conscionable 4 years ago. Tirzepatide inactive has beardown momentum and should let Eli Lilly to station fantabulous gross and net maturation implicit the mean term. But determination are plentifulness of different reasons to beryllium excited astir the company's prospects.

Eli Lilly launched Foundayo, an oral GLP-1, earlier this year, and it is besides seeing immense success, particularly with patients who had ne'er taken GLP-1 medicines before. This highlights the ample accidental successful the anti-obesity marketplace that Eli Lilly could pat into arsenic it launches new, differentiated products. The company's pipeline features candidates specified arsenic retatrutide, which volition apt people patients who request much assertive value nonaccomplishment options. Eli Lilly has 1 of the deepest value nonaccomplishment pipelines successful the industry, and the institution should thrust the soaring request for these products implicit the adjacent fewer years. Eli Lilly is besides making coagulated advancement successful different areas.

Several of the company's newer approvals, specified arsenic Kisunla, a cause for Alzheimer's illness (AD), could yet make implicit $1 cardinal successful yearly sales. Eli Lilly is processing a caller AD medicine, remternetug, that is presently successful signifier 3 studies. The institution is investigating remternetug successful subcutaneous injection and intravenous (IV) infusion delivery. Kisunla is lone administered via IV infusion, which requires patients to spell to the infirmary oregon immoderate different specialized halfway each 4 weeks. So, remternetug could beryllium much convenient for patients.

Read Entire Article